AzurBio

AzurBio's advisors have led EU launches inside global pharma companies, in regulatory affairs and market access. Today they help US and international biotechs take a first medicine to Europe. Meet the team.

In 30 minutes, a senior AzurBio advisor asks the questions your EU plan has to answer at month 0, and ranks what to do first. Complimentary, no preparation needed.

Teams that carry their US playbook over tend to find the gaps at their first EMA interaction, when the options are already narrower. Our white paper shows what changes, and what to prepare first.

Asking now costs you 30 minutes. Your first EU decisions shape the next two years: when you first meet EMA, how your pediatric plan and incentives are sequenced, what your dossier is built around. A senior AzurBio advisor will look at your program with you. Complimentary, no preparation needed, and useful whether or not we work together.

Before your EU strategy turns into budgets, timelines and a first EMA meeting, it deserves one outside read. In 30 minutes, a senior AzurBio advisor who has led EU launches goes through it with you: what EMA is likely to ask, what may need another look, what to do first. Complimentary, no preparation needed.

Could you say today what your Joint Clinical Assessment will need before you file with EMA? If you had to think, you are not behind. You have found a question worth asking now, rather than at Day 120. In 30 minutes, a senior AzurBio advisor asks the questions EMA will ask and points out what you may not have seen yet. Complimentary, no preparation needed.